SLU-PP-332 is a synthetic estrogen-related-receptor (ERR) agonist studied in metabolic and exercise-capacity laboratory models. The original overview of this page asks three questions: ERR agonism and mitochondrial research, preclinical exercise-mimetic model limits, and identity, solvent, and concentration verification. It is a small molecule, not a peptide.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.
ERR agonism and mitochondrial research
Billon and colleagues identified SLU-PP-332 as a synthetic ERR pan agonist that targets ERRα, ERRβ, and ERRγ, with the highest potency for ERRα, and they reported that it increased mitochondrial function and cellular respiration in a skeletal-muscle cell line (Billon et al., 2023). When administered to mice, the authors reported an increase in type IIa oxidative skeletal-muscle fibers and enhanced exercise endurance (Billon et al., 2023). Those statements are identity and model findings. They do not make the compound a peptide, and they are not a human protocol.
Preclinical exercise-mimetic limits
In a later paper, the same group explicitly named SLU-PP-332 and examined it in diet-induced obese and ob/ob mouse models of obesity and metabolic syndrome. They reported that administration mimicked exercise-related effects on whole-body metabolism, including increased energy expenditure and fatty-acid oxidation, with decreased fat-mass accumulation, reduced obesity, and improved insulin sensitivity in those models (Billon et al., 2024). Those are mouse-model observations. They are not a completed clinical program, they are not a diet or training substitute, and this draft does not transcribe dosing arms as a regimen.
Identity, solvent, and concentration verification
SLU-PP-332 should be documented with methods suited to a small molecule, including identity, impurity profiling, the solvent actually used, and the concentration written in the protocol. A purity percentage copied from a peptide template is not a complete file. This page does not prescribe a solvent or a concentration. Third-Party Peptide Testing, Explained and lot traceability still apply as documentation practices.
SLU-PP-332 was not found as a standalone published item in Velnacor’s current research-material catalog listing used for this draft. Use the product directory and the COA Library, then confirm whether a current SKU exists and which documents apply in the inquiry. For packing at supply scale, see wholesale peptides.
An “exercise-mimetic” heading is a literature frame, not a specification and not a human outcome. Mitochondrial or respiration assays, fiber-type observations, and whole-body metabolic endpoints in mice should be named separately in a protocol, and they should not be collapsed into a single marketing synonym. Solvent and concentration belong in that protocol; this page does not prescribe them. A later reader should be able to tell which ERR-subtype question the experiment actually asked.
Selected published literature
- Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, Kazantzis M, Chatterjee A, Chrivia J, Hayes ME, Xu W, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chemical Biology. 2023;18(4):756-771. doi:10.1021/acschembio.2c00720. PubMed 36988910.
- Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP. A synthetic ERR agonist alleviates metabolic syndrome. The Journal of Pharmacology and Experimental Therapeutics. 2024;388(2):232-240. doi:10.1124/jpet.123.001733. PubMed 37739806.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.